Clinical Trial Update: Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade [Phase 2]

View source ↗

Summary

A phase 2 trial evaluating chidamide plus camrelizumab as second-line therapy for advanced esophageal squamous cell carcinoma after prior PD-1 blockade.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• Chidamide (chidamide)

Snippet

Sponsor: The First Affiliated Hospital of Zhengzhou University | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN